Get the Stockscreener App
13.89
3.35%
0.45
After Hours:
13.85
-0.04
-0.29%
Intellia Therapeutics Inc stock is traded at $13.89, with a volume of 4.01M.
It is up +3.35% in the last 24 hours and up +11.21% over the past month.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
See More
Previous Close:
$13.44
Open:
$13.25
24h Volume:
4.01M
Relative Volume:
0.85
Market Cap:
$1.64B
Revenue:
$52.86M
Net Income/Loss:
$-480.19M
P/E Ratio:
-2.9617
EPS:
-4.6899
Net Cash Flow:
$-421.82M
1W Performance:
-10.04%
1M Performance:
+11.21%
6M Performance:
+16.92%
1Y Performance:
+34.20%
1-Day Range:
$13.07
$14.14
1-Week Range:
$12.55
$14.79
52-Week Range:
$5.90
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Name
Intellia Therapeutics Inc
Sector
Industry
Phone
857-285-6200
Address
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
13.89 | 1.59B | 52.86M | -480.19M | -421.82M | -4.6899 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.87 | 116.01B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.60 | 80.33B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
740.40 | 44.42B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.59 | 42.53B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
302.29 | 33.32B | 5.36B | 287.73M | 924.18M | 2.5229 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Nov-12-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-11-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-07-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-28-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-28-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-27-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-27-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-06-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Apr-21-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-05-25 | Initiated | H.C. Wainwright | Buy |
| Feb-28-25 | Downgrade | Goldman | Neutral → Sell |
| Feb-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-27-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-23-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Mar-14-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-24-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-19-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Sell |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Jun-16-22 | Initiated | BofA Securities | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Feb-18-22 | Initiated | William Blair | Outperform |
| Feb-07-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-22 | Initiated | Cowen | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
| Oct-05-21 | Initiated | Guggenheim | Buy |
| Sep-24-21 | Initiated | Stifel | Buy |
| Jun-28-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-11-21 | Initiated | H.C. Wainwright | Buy |
| May-07-21 | Upgrade | ROTH Capital | Neutral → Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-22-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-27-20 | Initiated | Truist | Buy |
| Oct-14-20 | Initiated | Wells Fargo | Overweight |
| Sep-18-20 | Initiated | Goldman | Buy |
| Feb-28-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-14-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-01-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-09-19 | Initiated | Robert W. Baird | Outperform |
| Jun-10-19 | Initiated | ROTH Capital | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Nov-02-18 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-29-18 | Initiated | Credit Suisse | Neutral |
| Sep-21-18 | Initiated | Raymond James | Mkt Perform |
| May-15-18 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-08-18 | Initiated | JMP Securities | Mkt Outperform |
| Nov-01-17 | Reiterated | Jefferies | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-05-16 | Upgrade | Jefferies | Hold → Buy |
View All
Intellia Therapeutics Inc Stock (NTLA) Latest News
Intellia Therapeutics: Why The Clinical Hold Lift Isn't A Total Victory (NASDAQ:NTLA) - Seeking Alpha
NTLA: Mid-year Phase 3 data could enable a first-in-class, one-time gene editing launch for HAE - TradingView
(NTLA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy? - Nasdaq
Cathie Wood's Intellia Therapeutics Surges 47%: Is It Too Late to Invest? - Intellectia AI
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM - mx.advfn.com
Cathie Wood’s ARK Made Just One Buy Last Session — And It’s A Biotech Stock Up Nearly 30% YTD - Stocktwits
Is Intellia Therapeutics (NTLA) Pricing Look Interesting After Strong Year-To-Date Share Gain? - simplywall.st
A Look At Intellia Therapeutics (NTLA) Valuation After Its Recent Share Price Rebound - Yahoo Finance
Amova Asset Management Americas Inc. Cuts Position in Intellia Therapeutics, Inc. $NTLA - MarketBeat
ARK Investment Management LLC Trims Stake in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Jones Trading Upgrades Intellia Therapeutics (NTLA) - Nasdaq
FDA again targets GLP-1 compounders; Intellia to restart heart disease trial - BioPharma Dive
Intellia Therapeutics (NASDAQ:NTLA) Upgraded at JonesTrading - MarketBeat
This Target Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday - Benzinga
NTLA Stock Upgrade: Jones Trading Raises Intellia Therapeutics t - GuruFocus
HC Wainwright Has Pessimistic Outlook of NTLA Q1 Earnings - MarketBeat
Brookline Capital Maintains Buy on Intellia Therapeutics Inc (NTLA) March 2026 - Meyka
Intellia (NTLA) CEO John M. Leonard awarded large option and RSU grants - Stock Titan
Intellia (NTLA) EVP receives stock awards and small tax-driven share sale - Stock Titan
Intellia Therapeutics (NTLA) CMO awarded options and RSUs in Form 4 filing - Stock Titan
Intellia Therapeutics (NTLA) CFO granted stock options and RSUs - Stock Titan
Intellia Therapeutics (NTLA) CSO awarded options and RSUs - Stock Titan
Intellia Therapeutics (NTLA) EVP gets stock awards and sells shares for taxes - Stock Titan
Intellia Therapeutics (NTLA) CAO awarded 17,250 restricted stock units - Stock Titan
Intellia Therapeutics (NASDAQ:NTLA) Given New $48.00 Price Target at Canaccord Genuity Group - MarketBeat
FDA’s lifting of clinical holds sends Intellia upwards - The Pharma Letter
Intellia Therapeutics Presents Longer-Term Clinical Data For Lonvoguran Ziclumeran - National Today
Intellia Therapeutics (NTLA) Highlights Promising Findings in He - GuruFocus
NTLA: Leerink Partners Raises Price Target and Maintains Outperf - GuruFocus
Leerink Partners Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price - MarketBeat
NTLA: RBC Capital Raises Price Target to $15, Maintains Sector P - GuruFocus
Intellia Therapeutics Stock Gains — FDA Lifts Clinical Hold On Pivotal Trial - Sahm
Royal Bank Of Canada Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price - MarketBeat
Wells Fargo Raises Price Target for Intellia Therapeutics (NTLA) to $15 | NTLA Stock News - GuruFocus
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026 - Bitget
Wells Fargo & Company Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price - MarketBeat
Intellia Therapeutics (NTLA) Highlights Promising Findings in Hereditary Angioedema Treatment - GuruFocus
Citizens Jmp Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price - MarketBeat
HC Wainwright Boosts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $30.00 - MarketBeat
Vanguard Group Inc. Acquires 192,651 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat
Chardan Raises Price Target on Intellia Therapeutics to $27 From $26, Keeps Buy Rating - marketscreener.com
NTLA Sees Price Target Raised by Citizens, Rating Maintained | N - GuruFocus
Intellia presents data on experimental gene therapy for hereditary angioedema - Investing.com
RBC Raises Price Target on Intellia Therapeutics to $15 From $9, Keeps Sector Perform, Speculative Risk - marketscreener.com
NTLA: HC Wainwright & Co. Raises Price Target to $30.00 | NTLA S - GuruFocus
Intellia Therapeutics Presents Longer-Term Clinical Data - GlobeNewswire
Demystifying Intellia Therapeutics: Insights From 4 Analyst Reviews - Benzinga
Intellia Therapeutics, Inc. $NTLA is Contrarius Group Holdings Ltd's 6th Largest Position - MarketBeat
Intellia Therapeutics Inc Stock (NTLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):